These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 33707742)

  • 21. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.
    Correia DV; d'Orey F; Cardoso BA; Lança T; Grosso AR; deBarros A; Martins LR; Barata JT; Silva-Santos B
    PLoS One; 2009 May; 4(5):e5657. PubMed ID: 19479075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer immunotherapy with γδ T cells: many paths ahead of us.
    Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
    Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal Cell Carcinoma-Infiltrating CD3
    Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
    Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies.
    Sebestyen Z; Prinz I; Déchanet-Merville J; Silva-Santos B; Kuball J
    Nat Rev Drug Discov; 2020 Mar; 19(3):169-184. PubMed ID: 31492944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
    Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
    Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
    Rei M; Pennington DJ; Silva-Santos B
    Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives of gammadelta T cells in tumor immunology.
    Kabelitz D; Wesch D; He W
    Cancer Res; 2007 Jan; 67(1):5-8. PubMed ID: 17210676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
    Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
    Front Immunol; 2020; 11():564499. PubMed ID: 33133075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.
    Brandes M; Willimann K; Bioley G; Lévy N; Eberl M; Luo M; Tampé R; Lévy F; Romero P; Moser B
    Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2307-12. PubMed ID: 19171897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
    Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
    Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphoantigens overcome human TCRVgamma9+ gammadelta Cell immunosuppression by TGF-beta: relevance for cancer immunotherapy.
    Capietto AH; Martinet L; Cendron D; Fruchon S; Pont F; Fournié JJ
    J Immunol; 2010 Jun; 184(12):6680-7. PubMed ID: 20483742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.
    Legut M; Cole DK; Sewell AK
    Cell Mol Immunol; 2015 Nov; 12(6):656-68. PubMed ID: 25864915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative view on vitamin C effects on αβ- versus γδ T-cell activation and differentiation.
    Peters C; Kouakanou L; Kabelitz D
    J Leukoc Biol; 2020 Jun; 107(6):1009-1022. PubMed ID: 32034803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. γδ T cell activation by bispecific antibodies.
    Oberg HH; Kellner C; Gonnermann D; Peipp M; Peters C; Sebens S; Kabelitz D; Wesch D
    Cell Immunol; 2015 Jul; 296(1):41-9. PubMed ID: 25979810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An unconventional TRAIL to cancer therapy.
    Chen HC; Dieli F; Eberl M
    Eur J Immunol; 2013 Dec; 43(12):3159-62. PubMed ID: 24136367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. γδ T cell responses: How many ligands will it take till we know?
    Vermijlen D; Gatti D; Kouzeli A; Rus T; Eberl M
    Semin Cell Dev Biol; 2018 Dec; 84():75-86. PubMed ID: 29402644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of Human Peripheral Blood γδ T Cells Expanded With Zoledronate.
    Kim M; Kim H; Han M; Hwang HJ; Kim H; Im HJ; Kim N; Koh KN
    Anticancer Res; 2021 Dec; 41(12):6031-6038. PubMed ID: 34848457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.